Stifel Nicolaus set a $36.00 price target on Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note released on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on VNDA. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a strong-buy rating to a hold rating in a report on Wednesday, August 8th. Cantor Fitzgerald assumed coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, August 22nd. They issued a neutral rating and a $26.00 price objective on the stock. Oppenheimer assumed coverage on shares of Vanda Pharmaceuticals in a report on Thursday, September 20th. They issued a buy rating and a $29.00 price objective on the stock. CIBC reaffirmed an outperform rating on shares of Vanda Pharmaceuticals in a report on Friday, September 21st. Finally, Citigroup increased their price objective on shares of Vanda Pharmaceuticals from $27.00 to $31.00 and gave the stock a buy rating in a report on Tuesday, October 16th. Seven investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. Vanda Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $33.00.

Vanda Pharmaceuticals stock opened at $28.94 on Monday. Vanda Pharmaceuticals has a 1 year low of $13.30 and a 1 year high of $33.44. The stock has a market capitalization of $1.31 billion, a PE ratio of -82.69, a price-to-earnings-growth ratio of 4.28 and a beta of 0.87.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.18. Vanda Pharmaceuticals had a net margin of 7.06% and a return on equity of 5.88%. The company had revenue of $49.13 million for the quarter, compared to the consensus estimate of $49.44 million. During the same period last year, the firm posted ($0.03) EPS. The company’s revenue for the quarter was up 18.9% on a year-over-year basis. On average, research analysts anticipate that Vanda Pharmaceuticals will post 0.21 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its holdings in shares of Vanda Pharmaceuticals by 2.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,681,250 shares of the biopharmaceutical company’s stock worth $32,028,000 after acquiring an additional 41,200 shares during the period. BlackRock Inc. increased its stake in Vanda Pharmaceuticals by 16.3% during the 2nd quarter. BlackRock Inc. now owns 4,960,924 shares of the biopharmaceutical company’s stock valued at $94,506,000 after buying an additional 693,922 shares during the period. Xact Kapitalforvaltning AB acquired a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $240,000. PNC Financial Services Group Inc. increased its stake in Vanda Pharmaceuticals by 25.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 279,485 shares of the biopharmaceutical company’s stock valued at $6,414,000 after buying an additional 55,911 shares during the period. Finally, Virginia Retirement Systems ET AL acquired a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $754,000. 99.33% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

See Also: How Does the Quiet Period Work?

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.